Platform Operations Engineer

Company news. Showing 21 of 66 posts Materna Medical announces successful $5 million B3 financing to support transformational year ahead. Materna Medical announced the successful close of its $5 million B3 financing round, positioning the company for a year of clinical, commercial, and operational advancement. The round was led by InnovaHealth Partners, Wavemaker360 Health, and Band of Angels, with support from existing investors. July 1, 2026 EliseAI hits $200M ARR after five consecutive years of 100% growth across housing and healthcare. EliseAI, the AI company automating complex housing and healthcare systems, announced it passed $200 million in annual recurring revenue (ARR), achieving 100% year-over-year growth for the fifth consecutive year. June 10, 2026 OCULOGICA announces FDA clearance for SNAP concussion test. Oculogica, a pioneer in the development of non-invasive tests for concussion, announced the FDA has granted a 510(k) clearance for SNAP. SNAP is a 90-second concussion test that combines eye tracking with symptom severity to provide a multi-modal concussion assessment for clinicians. June 4, 2026 Zenflow presents the BREEZE(TM) pivotal clinical trial at the American urological Association annual meeting. Zenflow, Inc. presented data from its BREEZE pivotal clinical trial demonstrating the efficacy and safety of the Zenflow Spring Implant & Delivery System, which was FDA approved in Dec. 2025 for the treatment of symptoms associated with benign prostatic hyperplasia, also known as enlarged prostate. May 18, 2026 How Sylvatex is harnessing the power of nature to win the battery race america can't afford to lose. Virginia Klausmeier founded Sylvatex - a California-based company with a single, audacious goal: to make the cathode better, cleaner, and cheaper than China, on American soil, using nature's own chemistry as the blueprint. May 15, 2026 Osteoboost featured in Vogue. Osteoboost, the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women, was featured in the May edition of Vogue. May is Osteoporosis Awareness Month and Women's Health Month. May 11, 2026 Tot Squad acquires AI doula startup Robyn. Tot Squad, a platform that supports new parents from registry through early parenthood, has acquired Robyn, a maternal health startup with an AI-powered doula trained on over 70,000 de-identified messages between real doulas and parents. May 7, 2026 Building plant-based cities with Another Tomorrow. Sustainable ready-to-wear brand Another Tomorrow hosted its third "New Earth Dialogues" installment with architect Lindsey Wikstrom - founding principal of Mattaforma and recent recipient of the Cooper Hewitt National Design Award - to discuss. May 4, 2026 Chromatic 3D Materials demonstrates Breakthrough in 3D printed rocket propellant. Chromatic 3D Materials announced successful prototype printing and static fire testing of its additively manufactured rocket propellant. The tests demonstrated that Chromatic's printed propellant can sustain combustion pressures beyond 1800 psi without structural failure, a critical milestone. April 29, 2026 Bairitone Health receives FDA Breakthrough Device Designation for its noninvasive technology designed for obstructive sleep apnea. Bairitone Health has received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its sleep sonar for anatomic polysomnography technology to pinpoint the root cause of airway obstruction in people with obstructive sleep apnea (OSA). April 28, 2026 Kind Designs and BMI OrganBank named 2026 Villalobos Award winners by the Angel Capital Association. Two Golden Seeds companies, Kind Designs and BMI OrganBank, named as winners of the 2026 Villalobos Award by the Angel Capital Association (ACA). This award recognizes the most innovative ideas financed by members of the ACA across two categories: Technology/Services/Consumer and Life Sciences. April 22, 2026 EliseAI named on the Forbes 2026 AI 50 list. Forbes' annual AI 50 list spotlights the most promising privately-held AI companies in the world. Under the leadership of CEO Minna Song, EliseAI continues to scale its AI platform, transforming operations across housing and healthcare, driving efficiency, automation, and better experiences. April 16, 2026 Osteoboost raises $8M to scale fda-cleared wearable for bone health in postmenopausal women. Osteoboost Health has closed an $8 million financing round to scale manufacturing, expand clinical research, and broaden commercial reach for its FDA-cleared prescription wearable for low bone density. The round was led by Ambit Health Ventures. April 15, 2026 Saladax Biomedical to expand international access to drug level testing for psychiatry and oncology. Saladax Biomedical, Inc., a leader in therapeutic drug monitoring (TDM) diagnostics for psychiatry and oncology, announced a distribution agreement with Thermo Fisher Scientific to expand global access to high-quality TDM assays that help clinicians optimize patient outcomes. April 7, 2026 Joylux launches reliefher(tm), the next generation of intimate skincare for midlife women. Joylux today announced the launch of reliefHER, a proprietary vaginal hydration melt formulated with 15 mg of hyaluronic acid (HA), up to three times the HA power found in many other products. April 6, 2026 Alcatraz raises $50 million to replace the badge with your face - without sacrificing privacy. Alcatraz, which makes an AI-powered physical access control system that authenticates employees without collecting personal data, has closed a $50 million Series B funding round, bringing total capital raised to more than $100 million. April 2, 2026 MedOne and Nanodropper announce early success of MediSplit program, demonstrating reduced cost, improved adherence, and reduced side effects. MedOne and Nanodropper, a leader in precision medication delivery solutions, recently announced early results from the MediSplit program, a value-based clinical care path designed to improve medication adherence and reduce side effects for patients using prescription eye drops. April 2, 2026 Madorra enrolls first patient in pivotal trial for non-hormonal vulvovaginal atrophy treatment. Madorra, a medical device company, has enrolled the first patient in its pivotal clinical trial evaluating the Madorra Therapy System for moderate to severe vulvovaginal atrophy - a milestone following the FDA's grant of Breakthrough Device Designation. March 30, 2026 Chippin receives $1 million grant to incorporate invasive catfish in pet nutrition. Chippin, Inc., a company that leverages planet-friendly ingredients and invasive species to create sustainable pet nutrition, has received a $1 million grant through the Meat and Poultry Processing Expansion Program to create a new market for invasive catfish in pet nutrition. March 30, 2026 Breakthrough Device Designation awarded to Hemex Health for Gazelle Hb Variant Test. Hemex Health, a medical diagnostics company focused on decentralized testing for blood-based conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Gazelle(R) Hb Variant Test. March 26, 2026 New clinical study shows Nanodropper microvolume delivery device provides superior efficacy, fewer side effects, and dramatically reduces early eyedrop bottle exhaustion. Nanodropper announced results from a randomized clinical trial demonstrating that microvolume eyedrop delivery using their adaptor achieved greater intraocular pressure reduction, fewer adverse effects, and significantly reduced premature bottle exhaustion compared with conventional eyedrops. March 25, 2026

EliseAI, an AI company automating housing and healthcare systems, has surpassed $200 million in annual recurring revenue, marking its fifth consecutive year of 100% year-over-year growth. The company now powers one in six apartments in the United States. EliseAI automates the entire resident journey in housing, from leasing enquiries to maintenance requests and renewals. In healthcare, it handles appointment scheduling, patient intake and reduces wait times, cutting administrative overhead by up to 25%. The platform addresses an industry problem costing over $600 billion annually in the US. The company has seen particular adoption among affordable housing providers operating under tight financial constraints. Co-founder and CEO Minna Song attributes the growth to solving real problems in essential industries where AI can have tangible impact.

EliseAI hits $200M ARR after five consecutive years of 100% growth across housing and healthcare. June 10, 2026 NEW YORK, June 10, 2026 - EliseAI, the AI company automating complex housing and healthcare systems, today announced it passed $200 million in annual recurring revenue (ARR), achieving 100% year-over-year growth for the fifth consecutive year. Housing and healthcare together account for more than 40% of the average American household budget. Both industries have been underserved by technology relative to their size and complexity. Automating them at scale requires state-by-state compliance, deep workflow integration, and edge-case handling that general-purpose tools cannot deliver. EliseAI has been building inside that complexity in close partnership with operators, becoming core to how they run their properties and practices. "The industries where AI matters the most are not the ones getting the most attention," said Minna Song, co-founder and CEO of EliseAI. "We started in housing, and then expanded to healthcare, because we believed AI could fundamentally change how essential industries operate. Five years of 100% growth at this stage is rare, and it happens when the problems are real and the product becomes more valuable the deeper it is embedded." EliseAI powers one in six apartments in the United States, automating the entire resident journey - from answering leasing inquiries and handling maintenance requests to following up on renewals. In healthcare, it supports patients by scheduling appointments, guiding them through intake forms, and reducing time spent waiting. The need is most acute where the margin for error is lowest. Affordable housing providers, operating under the tightest financial constraints and serving residents with the fewest alternatives, are increasingly turning to EliseAI because operational consistency is not optional when staffing is lean and residents depend on every part of the system working. It is one of the places where AI can have the most tangible impact on people's lives. "Affordable housing operators have always had to do more with less," said Joshua Greenblatt, Managing Principal at Vesta Corporation. "The compliance requirements are strict, the teams are lean, and the residents we serve often have no safety net if something falls through the cracks. EliseAI takes on the routine work that used to bottleneck our staff, so our teams can spend their time on the people, not the paperwork. For an industry that technology largely bypassed for decades, that shift is real - and it matters." Healthcare administrative costs total in excess of $600 billion annually in the U.S., $150 billion of that attributable to missed appointments alone, driven by excessive manual tasks, fragmented systems, and chronic underinvestment in technology. EliseAI is tackling the problem at the point of highest friction: front-desk and call center operations. Its platform handles complex workflows including multi-step scheduling, prior authorizations, patient intake, and nuanced clinical inquiries, accurately, compliantly, and empathetically, cutting overhead by up to 25%, slashing wait times, and reducing abandoned calls. As a result, EliseAI is increasingly where the patient experience begins. For practices facing staffing shortages and rising call volumes, the company is moving beyond task automation to become a core layer of healthcare operations. "EliseAI's growth shows what it takes to build vertical AI at scale: deep domain expertise, workflow-level product insight, and clear customer ROI," said Alex Immerman, partner, a16z Growth. "Today's news reflects EliseAI's real impact on their customers' bottom lines and sets the stage for continued growth." About EliseAI EliseAI transforms complex housing and healthcare systems. By deeply integrating into workflows and automating operations, it makes them efficient and cuts costs for all. Its platform helps property managers handle leasing, maintenance and resident engagement. EliseAI replaces fragmented tools with one integrated system that reduces manual work and improves accessibility and experience for residents and patients alike. The company is based in New York with offices in San Francisco, Boston, Chicago and Toronto and is actively hiring across all locations. To learn more, visit www.eliseai.com/careers.